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Background: The optimal surgical management of pancreatic neuroendocrine tumors in patients with
multiple endocrine neoplasia type 1 is controversial. This study sought to compare clinicopathologic
characteristics and outcomes of multiple endocrine neoplasia type 1eassociated and sporadic pancreatic
neuroendocrine tumors from a large multi-national database.
Methods: A multi-institutional, international database of patients with surgically resected pancreatic
neuroendocrine tumors was analyzed. The cohort was divided into 2 groups: those with multiple endocrine neoplasia type 1 versus those with sporadic disease. Clinicopathologic comparisons were made.
Overall and disease-free survival were analyzed. Propensity score matching was used to reduce bias.
Results: Of 651 patients included, 45 (6.9%) had multiple endocrine neoplasia type 1 and 606 sporadic
pancreatic neuroendocrine tumors. Multiple endocrine neoplasia type 1eassociated pancreatic neuroendocrine tumors were more common in younger patients and associated with multifocal disease at the
time of surgery and higher T-stage. Lymph node involvement and the presence of metastasis were
similar. Total pancreatectomy rate was 5-fold higher in the multiple endocrine neoplasia type 1 cohort.
Median survival did not differ (disease-free survival 126 months multiple endocrine neoplasia type 1 vs
198 months sporadic, P > .5). After matching, survival remained similar (overall survival not reached in
either cohort, disease-free survival 126 months multiple endocrine neoplasia type 1 vs 198 months
sporadic, P > .5). Equivalence in overall survival and disease-free survival persisted even when patients
who underwent subtotal and total pancreatectomy were excluded.
Conclusion: Multiple endocrine neoplasia type 1eassociated pancreatic neuroendocrine tumors are
more common in younger patients and are associated with multifocality and higher T-stage. Survival for
patients with multiple endocrine neoplasia type 1eassociated pancreatic neuroendocrine tumors is
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comparable to those with sporadic pancreatic neuroendocrine tumors, even in the absence of radical
pancreatectomy. Consideration should be given to parenchymal-sparing surgery to preserve pancreatic
function.
© 2022 Elsevier Inc. All rights reserved.

Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal
dominant endocrine neoplastic syndrome, associated with development of multiple tumors of the pituitary, parathyroid and foregut
neuroendocrine tissue/organs.1e3 Pancreatic neuroendocrine
tumors (PNET) have been reported to occur in 30% to 80% of
patients with MEN1 and represent the leading cause of mortality in
this population.2e5 MEN1-associated PNET are typically diagnosed
at a younger age.34 It has been suggested that MEN1-associated
PNET may exhibit a less aggressive phenotype compared to their
sporadic counterparts.3,4 There is a paucity of studies, however, that
have directly compared clinicopathological characteristics and
survival outcomes in patients with MEN1 versus sporadic PNETs.
Surgical criteria for MEN-associated PNET are not well established,1,4e6 both with regard to timing and type of surgery.4 Previously, PNETs were resected based on hormone functionality, or if
the diameter exceeded 1 cm in nonfunctioning tumors.5 With the
increasing recognition that some nonfunctioning PNETs may follow
an indolent course, the size cut-off for resection has been the topic
of much debate. Most groups recommend surgery for tumors >2
cm in diameter,1,4,7 and even up to >3 cm in diameter,4,8 while
others consider tumors of 1.5 cm with annual growth of 0.5 cm for
resection.3 Once the decision has been made to operate, the primary goal of surgery is to reduce the risk of distant metastasis while
preserving endocrine and exocrine pancreatic function. However,
there is no clear consensus regarding the optimal extent of surgical
resection. Many groups favor parenchymal-sparing procedures
(akin to those performed for sporadic tumors), due to the notion
that MEN1-associated PNET generally harbor low oncological risk
with a favorable prognosis. Conversely, the multifocality of MEN1associated PNET, with each lesion harboring its own degree of
growth potential and pattern of hormone secretion, has led others
to recommend more extensive resections, especially in the absence
of reliable biomarkers of malignant progression. Aggressive procedures that have been advocated include subtotal distal pancreatectomy with enucleation of lesions in the pancreatic head and/or
duodenum and even total pancreatectomy or multivisceral
resection.9e14
Presently, there are no uniform guidelines with criteria for
surgical resection of MEN1-associated PNET, with most recommendations extrapolated from studies of sporadic PNET. Moreover,
there is limited knowledge regarding the clinicopathological characteristics of MEN1-associated PNET in comparison to sporadic
tumors. Therefore, this study sought to improve knowledge of
MEN1-associated PNET and facilitate optimal surgical decision
making in patients with these challenging tumors.
Methods
An international, multi-institutional collaborative database was
used to conduct this study, using a cohort study design. Patient data
were included from Stanford University, United States; Providence
Portland Medical Center, United States; University of Oxford, UK;
University of Cambridge, UK; University College London, UK; University of Edinburgh, UK; University of Auckland, New Zealand; and
University Hospital Madrid Sanchinarro, Spain. All institutions
provided Institutional Review Board (IRB) approval for use of the

data, under a “minimal risk” protocol. The collection, deidentiﬁcation, and storage of the data were performed according to previously published methods.15 In brief, data were collected from 1999
to 2016. Only the index surgery was considered. A standardized
data dictionary was used to ensure data consistency. After deidentiﬁcation, data were centrally stored at a single site (Stanford).
Inclusion criteria for this study were patients aged 18 years old
who underwent surgery for MEN1-associated or sporadic PNET.
Criteria for the diagnosis of MEN1 were in accordance with current
clinical practice guidelines, including: (1) the presence of a germline MEN1 mutation; (2) the occurrence of 2 or more primary
MEN1-associated endocrine tumors; or (3) the occurrence of at
least 1 MEN1-related tumor in a patient with a ﬁrst-degree relative
with conﬁrmed MEN1.16 Once patients were identiﬁed, clinicopathologic parameters and survival data were extracted and
analyzed. In patients with multiple tumors, the largest tumor was
used to deﬁne T-stage, differentiation, and Ki-67.
Statistical analysis
Continuous and normally distributed data were expressed as
mean (standard deviation) and compared for equivalence with the
Student’s t test (2-tailed). Continuous data with non-normal
distribution were expressed as median [interquartile range] and
compared for equivalence with the Mann-Whitney U test.
Uniformly distributed multilevel categorical variables were
compared with Pearson’s c2 test, while Fisher exact test was used to
compare categorical variables with nonuniform distribution. Survival analysis was performed using the method of Kaplan and
Meier17 with overall survival (OS) deﬁned as time from surgical
resection to death or censor. Disease-free survival (DFS) was
deﬁned as time from presumed R0 resection to censor or death
without disease. Patients with incomplete survival data were
censored at the date of last correspondence or follow-up. Survival
curves were compared using the log-rank test.
Matching methods
In an effort to reduce selection bias, the propensity score was
calculated using logistic regression according to the method
outlined by Rosenbaum and Rubin.18e20 Covariates included in the
propensity score calculation were: age, gender, tumor size, and
T-stage. A matching ratio of 2:1 was targeted. Patients were
matched between the sporadic and MEN1 cohorts according to
their propensity scores. This was done by ﬁrst ordering patients by
propensity score, and then selecting 1 case and 2 control patients
according to the nearest score to the case in question. All 3 patients
were then removed from further consideration. Nearest neighbor
matching without replacement was performed using a greedy
matching algorithm and application of Mahalanobis distance
caliper. If 2 previously unused control subjects were not available
for each treated subject, then only 1 control was matched for that
subject. This can result in incomplete matching sets. Propensity
score histograms and scatter plots for the matched and unmatched
patients were computed. Intergroup comparisons were made after
matching. Propensity scores and matching were performed using
the MatchIt package in R.21e23 Statistical analysis was performed
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with R version 3.5.2 “Eggshell Igloo” (R Foundation for Statistical
Computing, Vienna, Austria, www.r-project.org).24

Table I
Cohort demographics, pathologic characteristics, and outcomes

Results
The query identiﬁed 651 patients who met inclusion criteria, of
which 45 patients were diagnosed with MEN1-associated PNET and
606 with sporadic PNET (Table I). Patients with MEN1 were diagnosed at a younger age compared to those with sporadic PNET.
MEN1-associated PNET were also more often functional, located in
multiple regions of the pancreas, and multifocal on histopathological examination. Lymph node involvement, the presence of
distant metastasis, and the degree of tumor differentiation did not
differ signiﬁcantly between the 2 groups. However, MEN1associated tumors generally were resected with a higher T-stage
although neither grade nor Ki67 were different when compared to
sporadic tumors (Table I). While the proportion of pancreaticoduodenectomies and distal pancreatectomies were similar
between the 2 groups, the rate of total pancreatectomy was 5 times
higher in the MEN1 cohort. The median length of follow-up for the
entire study population was 47 (IQR 24e74) months, and it was
somewhat longer in MEN1 patients compared to those with sporadic tumors (57 months vs 46 months, P ¼ .05). Survival analysis
did not show substantial differences between groups as median
overall survival (OS) was not reached in the MEN1 cohort versus
201 months in the sporadic PNET cohort. Median disease-free
survival (DFS) was 126 months in the MEN1 cohort versus 198
months in the sporadic cohort, but these curves were not statistically different (Figure 1).
Matched results
Matched intergroup comparisons can be seen in Table II, with
good balance achieved among the matched parameters. Histograms and jitter plots of the matched results are shown in Figure 2
and demonstrate good performance with appropriate exclusion of
outliers. Despite propensity matching, there was a persistent
intergroup difference in tumors located in multiple regions of the
pancreas for MEN1 patients as well as the presence of histopathologically multifocal disease. Matched patients were found to have
no difference in grade or Ki67 index on ﬁnal pathologic analysis. In
the matched cohort, there was a persistently higher proportion of
total pancreatectomy performed in the MEN1 group, although this
difference was not statistically signiﬁcant. In addition, survival
remained similar between sporadic and MEN patients (median OS
was not reached in either cohort and median DFS was 126 months
in the MEN1 cohort vs 198 months in sporadic cohort, P > .5;
Figure 3). OS and DFS equivalence persisted even when patients
who underwent subtotal and total pancreatectomy were excluded
(median OS and DFS were not reached in either cohort).
Discussion
This large international multicenter cohort study conﬁrms that
MEN1-associated PNET are identiﬁed at a younger age, are more
likely to appear as multiple lesions distributed throughout the
pancreas with multifocality on histology, and are more often
functional compared to sporadic tumors. Furthermore, patients
with MEN1 are signiﬁcantly more likely to be treated with total
pancreatectomy. Importantly, OS and DFS after surgical resection
did not differ between the MEN1 and sporadic cohorts, even when
patients who underwent total pancreatectomy were excluded from
the analysis. This study shows that while MEN1-associated PNET
possess distinct clinicopathological features compared to sporadic
PNET, survival outcomes are comparable in both groups, even in the
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Age (median [IQR])
Female sex
Functional
Functional type
Gastrinoma
Insulinoma
Glucagonoma
VIPoma
Somatostatinoma
Lesion location
Head
Neck
Body
Tail
Multiple
Final Ki67, median [IQR]
Grade (% of available)
Low
Intermediate
High
Histopathologically multifocal
No
Yes
Missing
Node positive
Metastatic disease
Differentiation
Missing
Well differentiated
Moderately differentiated
Poorly differentiated
T-Stage
1
2
3
4
Operation
Whipple
Distal
Subtotal
Total
Enucleation
Central
Other

Sporadic

MEN-Associated

n ¼ 606

n ¼ 45

58 [49e67]
299 (49.4%)
159 (29.6%)

46 [39e54]
27 (60.0%)
21 (46.7%)

18 (11.3%)
103 (64.8%)
12 (2.2%)
7 (1.3%)
19 (3.5%)

8
6
2
1
4

222 (36.7%)
32 (5.3%)
110 (18.2%)
227 (37.5%)
14 (2.3%)
2.0 [1.0e5.0]

10 (22.2%)
2 (4.4%)
6 (13.3%)
12 (26.7%)
15 (33.3%)
1.7 [1.0e4.0]

292 (59.8%)
177 (36.3%)
19 (3.9%)

23 (59.0%)
16 (41.0%)
0 (0%)

475 (78.8%)
113 (18.6%)
16 (2.6%)
180 (30.7%)
110 (18.4%)

12 (26.7%)
32 (71.1%)
1 (2.2%)
13 (28.9%)
10 (22.2%)

173 (28.5%)
402 (66.3%)
16 (2.6%)
15 (2.5%)

6 (13.3%)
38 (84.4%)
1 (2.2%)
0 (0.0%)

146 (24.1%)
94 (15.5%)
34 (5.6%)
332 (54.8%)

8 (17.8%)
3 (6.7%)
0 (0.0%)
34 (75.6%)

167 (27.6%)
270 (44.6%)
60 (9.9%)
20 (3.3%)
76 (12.5%)
5 (0.8%)
8 (1.3%)

10 (22.2%)
19 (42.2%)
5 (11.1%)
7 (15.6%)
2 (4.4%)
1 (2.2%)
1 (2.2%)

P

<.001
.224
.027

(38.1%)
(28.6%)
(9.5%)
(4.8%)
(19.0%)
<.001

.230
.418

<.001

.935
.666
.082

.034

.004

IQR, interquartile range; MEN, multiple endocrine neoplasia.

absence of aggressive pancreatic resections. These ﬁndings call into
question the necessity of subtotal or total pancreatectomy as the
initial procedure of choice for MEN1-associated PNET and support
the argument for performing organ-sparing resections, whenever
oncologically and technically feasible.
Unlike other MEN1 manifestations (such as primary hyperparathyroidism and pituitary adenoma) for which studies
comparing clinicopathological features and outcomes with sporadic disease have been published,25e27 very few series have
compared MEN1 versus sporadic PNETs.3,28 A previous study by
Norton et al focused solely on comparing MEN1 with sporadic
Zollinger-Ellison syndrome,28 while the study by Chiloiro et al
included a full spectrum of functioning and nonfunctioning PNETs
but only contained 45 patients, 13 of whom had MEN1.3 In
concordance with the present study’s ﬁndings, the authors of the
latter study found that MEN1-associated PNETs were diagnosed at a
younger age and were more likely to be multifocal. The small
patient numbers in this study, however, precluded further analysis
of survival outcomes. Therefore, these data are a substantial
contribution to the limited body of literature comparing outcomes
in MEN and sporadic PNET.
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Figure 1. Survival of resected patients (unmatched cohort). MEN, multiple endocrine neoplasia; PNET, pancreatic neuroendocrine tumor.

Table II
Matched comparisons
Sporadic

Age, median [IQR]
Female sex
Lesion location
Head
Neck
Body
Tail
Multiple
Final Ki67, median [IQR]
Grade (% of available)
Low
Intermediate
High
Histopathologically multifocal
No
Yes
Missing
Node positive
Metastatic disease
Differentiation
Missing
Well differentiated
Moderately differentiated
Poorly differentiated
T Stage
1
2
3
4
Operation
Whipple
Distal
Subtotal
Total
Enucleation
Central/Other

MEN-Associated

n ¼ 65

n ¼ 36

51.0 [39.0e60.0]
38 (58.5%)

49.5 [42.5e54.5]
22 (61.1%)

22 (33.8%)
2 (3.1%)
10 (15.4%)
28 (43.1%)
3 (4.6%)
3.0 [1.5e5.0]

10 (27.8%)
2 (5.6%)
4 (11.1%)
9 (25.0%)
11 (30.6%)
2.0 [1.0e4.0]

21 (46.7%)
23 (51.1%)
1 (2.2%)

15 (55.6%)
12 (44.4%)
0 (0%)

52 (80.0%)
9 (13.8%)
3 (4.6%)
18 (27.7%)
12 (18.5%)

10 (27.8%)
25 (69.4%)
1 (2.8%)
8 (22.2%)
7 (19.4%)

17 (26.2%)
44 (67.7%)
3 (4.6%)
1 (1.5%)

5 (13.9%)
30 (83.3%)
1 (2.8%)
0 (0.0%)

11 (16.9%)
9 (13.8%)
3 (4.6%)
42 (64.6%)

7 (19.4%)
3 (8.3%)
0 (0.0%)
26 (72.2%)

17 (26.2%)
35 (53.8%)
4 (6.2%)
1 (1.5%)
8 (12.3%)
0 (0.0%)

9 (25.0%)
14 (38.9%)
4 (11.1%)
5 (13.9%)
2 (5.6%)
2 (5.6%)

P

.694
.962
.007

.15
.6

<.001

.715
1
.373

.469

.065

IQR, interquartile range; MEN, multiple endocrine neoplasia.

The extent of surgical resection for MEN1-associated PNET
ranges from enucleation of a single tumor to subtotal or total
pancreatectomy. Historically, most authors have recommended
against total pancreatectomy as the index operation in MEN1
patients, due to the morbidity associated with brittle diabetes and
exocrine insufﬁciency. However, modern pancreatic enzyme formulations and improvements in blood glucose control via insulin
infusion pumps have reduced the metabolic sequelae of total
pancreatectomy, leading some to suggest that this procedure may
be a potentially viable option for risk-reduction surgery with no
risk of postoperative pancreatic ﬁstula (POPF).29 Reports of surgical
management of MEN1-associated PNET have demonstrated a
relatively high rate of perioperative complications, mainly consisting of grade B/C POPF, suggesting that parenchymal-sparing
surgery in this population is not without risk.30,31 Interestingly,
this study found that MEN1 patients had a 5-fold higher rate of total
pancreatectomy compared to patients with sporadic PNET, which
may reﬂect increased enthusiasm for this approach due to the
reasons mentioned above, as well as a desire to minimize the
occurrence of POPF in a group that is at high risk for this complication. There was no speciﬁc strategy of performing total pancreatectomy for patients with MEN-1 in any of the participating
institutions in this study, and the distribution of date of surgery was
not skewed over the course of the study period.
An alternative operative strategy involves minimal resection at
the outset, in order to preserve as much pancreatic function as
possible, with further organ-sparing reoperation(s) when
recurrences occur.32,33 Albers et al justify this approach based on
data that suggest that reoperative surgery for MEN1-associated
PNET does not entail an additional risk of morbidity compared
with initial resection and the observation that some patients may
not require reoperation until >30 years after their index procedure.32 Prior studies of recurrent intervention in patients with
MEN1-associated PNET have shown that this approach can be
effective at long-term control of the disease.6 On the other hand,
some studies have suggested that minimal surgical approaches in
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the form of enucleation have no place in the management of MEN1associated PNET, due to higher cure rate associated with formal
resection.34 With the increasing adoption of new imaging techniques such as endoscopic ultrasound and 68Ga-DOTA0-Tyr3-

Matched Treated
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Density
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Propensity Score
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Matched Control

2

Limitations

1

4

6

Density

8

3

0.8

octreotide (68Ga-DOTATOC) positron emission tomography-CT
(PET-CT), preoperative identiﬁcation of multifocal disease may
facilitate a more bespoke approach to surgical management of
these tumors.35
At present, it is not clear whether certain subgroups of MEN1
patients with PNET are more or less predisposed to developing
metastatic progression and/or recurrence (and would therefore
beneﬁt from upfront aggressive resection versus less extensive surgery). Several tentative genotype-phenotype correlations have been
proposed,36 including a higher risk of developing aggressive PNETs
in individuals with mutations in exon 2 or the N- or C-terminal regions of the MEN1 gene,2,37 or in those with mutations resulting in
loss of the JunD and CHES1 binding domains.38,39 However, these
ﬁndings have yet to be validated in independent cohorts, and information regarding genotype does not currently factor into the
surgical decision making process in MEN1 patients with PNET.
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5
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0.4
Propensity Score

0.6

0.8

0.0

0.2

0.4
Propensity Score

Figure 2. Matching performance plots.

0.6

0.8

This study is limited by its retrospective and nonrandomized
nature. Although the cohort size is substantial, there is still limited
power due to the rarity of these tumors, and signiﬁcant interinstitutional heterogeneity in the treatment approaches taken in
patient management, which introduces selection bias that is
nonuniform across surgeons and centers. A portion of the observed
recurrence in MEN-1 patients were likely new primary tumors,
whereas in sporadic patients these may be true recurrences.
However, it is not possible from the data available in this study to
distinguish between these 2 phenomenadalthough it may be an
area for future inquiry. Re-resection cases were not captured and
are not available for analysis, which limits the possibility of
analyzing re-resection outcomes after parenchymal sparing surgery. Pathologic assessment is nonuniform from center to center,
and this may introduce further reporting bias into the data. In
addition, the higher T-stage at presentation in the MEN population
may represent an underlying effort on the part of individual surgeons to delay surgery until after tumors have reached 2 cm in size.
Because this was not a uniformly applied standard, it likely contributes to some selection bias and may explain the skew in T-stage

Figure 3. Survival of resected patients (matched cohort).
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at presentation in the MEN population. Furthermore, because not
every patient in the present cohort underwent mutational analysis,
the possibility that some patients were MEN1 phenocopies (ie, they
did not harbor MEN1 mutations, and/or may have harbored mutations other genes known to result in an MEN1-like phenotype,
such as CDKN1B, CDC73, CASR, and AIP) cannot be ruled out.16 As
previously described,15 these data are subject to variations in
completeness and reporting, a situation that the authors have
endeavored to mitigate insofar possible with careful data management and reporting. The authors have attempted to address
other sources of selection bias and confounders through the use of
propensity score matching as a means of bias reduction.
In conclusion, MEN1-associated PNET occur more frequently in
younger patients and are more likely to present with multifocality
and at a higher T-stage compared to sporadic tumors. Nonetheless,
survival for patients with MEN-associated PNET is excellent and
does not differ signiﬁcantly from sporadic PNET. Although MEN1
patients underwent total pancreatectomy at 5 times the rate of
those with sporadic tumors, this may not be necessary in order to
ensure long-term survival. Consideration should be given toward
performing parenchymal-sparing surgical interventions in order to
preserve pancreatic function in this cohort of patients.
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